Evidence map›Paper›PMID 34634077›Full record

ArticlePloS one2021

Neuroinductive properties of mGDNF depend on the producer, E. Coli or human cells.

Dzhirgala V Shamadykova, Dmitry Y Panteleev, Nadezhda N Kust, Ekaterina A Savchenko, Ekaterina Y Rybalkina, Alexander V Revishchin, Galina V Pavlova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Dzhirgala V ShamadykovaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0003-3665-667X
Dmitry Y PanteleevInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
Nadezhda N KustInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
Ekaterina A SavchenkoBurdenko Neurosurgical Institute, Moscow, Russia.
Ekaterina Y RybalkinaBlokhin Russian Cancer Research Center, Moscow, Russia.
Alexander V RevishchinInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
Galina V PavlovaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
Institute of Gene Biology · RUInstitute of Higher Nervous Activity and Neurophysiology · RUBurdenko Neurosurgery Institute · RURussian Cancer Research Center NN Blokhin · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The glial cell line-derived neurotrophic factor (GDNF) is involved in the survival of dopaminergic neurons. Besides, GDNF can also induce axonal growth and creation of new functional synapses. GDNF potential is promising for translation to treat diseases associated with neuronal death: neurodegenerative disorders, ischemic stroke, and cerebral or spinal cord damages. Unproductive clinical trials of GDNF for Parkinson's disease treatment have induced to study this failure. A reason could be due to irrelevant producer cells that cannot perform the required post-translational modifications. The biological activity of recombinant mGDNF produced by E. coli have been compared with mGDNF produced by human cells HEK293. mGDNF variants were tested with PC12 cells, rat embryonic spinal ganglion cells, and SH-SY5Y human neuroblastoma cells in vitro as well as with a mouse model of the Parkinson's disease in vivo. Both in vitro and in vivo the best neuro-inductive ability belongs to mGDNF produced by HEK293 cells. Keywords: GDNF, neural differentiation, bacterial and mammalian expression systems, cell cultures, model of Parkinson's disease.

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsDisease Models, AnimalEscherichia coliGanglia, SpinalGlial Cell Line-Derived Neurotrophic FactorHEK293 CellsHumansMiceMice, Inbred C57BLNeuronal OutgrowthNeuronsNeuroprotective AgentsParkinson DiseasePC12 CellsRats1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineGlial Cell Line-Derived Neurotrophic FactorNeuroprotective AgentsRecombinant ProteinsTyrosine 3-Monooxygenase

Identifiers

PMID34634077
PMCPMC8504721
OpenAlexW3207335305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.